Apogee Therapeutics (APGE) Cash from Financing Activities (2022 - 2026)

Apogee Therapeutics (APGE) has reported Cash from Financing Activities for 5 consecutive years, with $411.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 66004.02% year-over-year to $411.2 million; the TTM figure through Mar 2026 stood at $807.0 million (up 1685.04% YoY), while the FY2025 annual figure was $396.5 million, down 19.92% from the prior year.
• Cash from Financing Activities advanced to $411.2 million in Q1 2026 per APGE's latest filing, from $375.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $450.5 million in Q1 2024 and bottomed at -$213000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $137.2 million across 5 years, with a median of $19.7 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 100.13% — and 2026, when it jumped 66004.02%.
• Apogee Therapeutics' Cash from Financing Activities stood at $158.5 million in 2022, then sank by 100.13% to -$213000.0 in 2023, then jumped by 20924.41% to $44.4 million in 2024, then soared by 745.32% to $375.0 million in 2025, then climbed by 9.66% to $411.2 million in 2026.
• Business Quant data shows APGE's Cash from Financing Activities at $411.2 million in Q1 2026, $375.0 million in Q4 2025, and $19.7 million in Q3 2025.